ERR2208962
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- CHOLESTEROL_HOMEOSTASIS+0.400
- FATTY_ACID_METABOLISM+0.400
- INTERFERON_ALPHA_RESPONSE+0.400
- MYC_TARGETS_V2+0.400
- OXIDATIVE_PHOSPHORYLATION+0.400
- BILE_ACID_METABOLISM+0.300
- COAGULATION+0.300
- E2F_TARGETS+0.300
- INTERFERON_GAMMA_RESPONSE+0.300
- MTORC1_SIGNALING+0.300
Top 10 suppressed
- WNT_BETA_CATENIN_SIGNALING-0.400
- ANGIOGENESIS-0.300
- MYOGENESIS-0.300
- NOTCH_SIGNALING-0.300
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.200
- PI3K_AKT_MTOR_SIGNALING-0.200
- TGF_BETA_SIGNALING-0.200
- UV_RESPONSE_DN-0.200
- HEDGEHOG_SIGNALING-0.100
- KRAS_SIGNALING_UP-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-BH-A0HB-01A-11R-A056-07 | — | B | 0.786 |
| 2 | 20100231.Her2HRpos | — | C | 0.768 |
| 3 | MNG626 | — | — | 0.765 |
| 4 | 1a68a242-045b-4566-afd7-192df87b02d3 | — | — | 0.763 |
| 5 | TCGA-AO-A0J2-01A-11R-A034-07 | — | C | 0.763 |
| 6 | TCGA-AN-A0AM-01A-11R-A034-07 | — | C | 0.755 |
| 7 | 992ce1bc-46a2-4f57-ac7a-c6368c69c67c | — | — | 0.747 |
| 8 | X1ce4a106.c532.4678.a6de.8e89f5123c73 | — | cohortMD2 | 0.744 |
| 9 | TCGA-BA-A6DD-01A-12R-A31N-07 | — | — | 0.742 |
| 10 | 7c8246a6-3f2c-42e1-b09f-959cfbf7fd5a | — | — | 0.739 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| CHOLESTEROL_HOMEOSTASIS | 0.400 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.400 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.400 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.400 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.400 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.300 | Inavolisib | — uncovered |
| COAGULATION | 0.300 | Binimetinib | — uncovered |
| E2F_TARGETS | 0.300 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.300 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.300 | Inavolisib | — uncovered |
| PEROXISOME | 0.300 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.200 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.200 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.200 | Temsirolimus | — uncovered |
| COMPLEMENT | 0.200 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.200 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.200 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.200 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.200 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.200 | Inavolisib | — uncovered |